Aptus Pharma Limited (BSE: 544529) is a Rajkot, Gujarat-based company in the Pharmaceutical Product Distribution industry. With a market capitalisation of ₹837 Cr, it ranks #1,678 by market cap among the 6,197 Indian listed companies on FinBizNet, and #4 of 13 in Pharmaceutical Product Distribution. At ₹497.00 (as of 16 Nov 2026), the share price is 2.7% below its 52-week high of ₹510.90 and 754.0% above its 52-week low of ₹58.20. The share price is up 754.0% over one year and up 92.5% over three months.
| Current Price | ₹497.00 |
|---|---|
| Market Cap | ₹837 Cr |
| BSE Code | 544529 |
| Sector | Health Care > Health Care Equipment and Services > Health Care Providers and Services |
| Sub-Industry | Health Care Distributors > Pharmaceutical Product Distribution |
| P/E Ratio | 156.8 |
| Return on Assets | 13.46% |
| 52-Week Range | ₹58.20 – ₹510.90 |
| 1-Year Price Change | +754.0% |
| 3-Month Price Change | +92.5% |
| Beta (1Y) | -0.24 |
| Headquarters | Rajkot, Gujarat |
| Website | aptus-pharma.com |
Promoters held 23.86% of Aptus Pharma Limited's shares as of Jun 2026, against 40.37% in Jun 2025 (−16.51 percentage points). Delivery averaged 100.0% of traded volume across 15 BSE sessions (21 Oct 2026 – 13 Nov 2026).
Aptus Pharma Limited engages in the marketing and distribution of finished pharmaceutical formulations. The company operates through four divisions: Aptus Pharma, Pioneer division which includes marketing of acute therapies including general anti-infectives, pain management, antacids, and gastrointestinal drugs; Aptus CD Care, Cardiac Diabetic division which includes marketing of chronic therapies, including anti-hypertensive, anti-diabetic, and lipid-lowering; Aptus Wellcare offers wellness and nutraceutical products, over-the-counter (OTC) formulations, and personal care products; and Aptus Global, export division engages in exploring and developing opportunities in overseas markets, semi-regulated and emerging countries. It also offers anti-infectives, gastrointestinal, antacids, anti-allergic and respiratory, nutritional supplements, pain management, neuro-psychiatric, cardiovascular, antidiabetic, lipid-lowering, and general wellness products. Its products are available in balms,
1. Pharmaceuticals, Medicinal Chemicals, and Botanical Products-This segment engages in the marketing and distribution of finished pharmaceutical formulations. 2. NA-NA 3. NA-NA 4. NA-NA
1. Pharmaceuticals, Medicinal Chemicals, and Botanical Products-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Entero Healthcare Solutions Limited | ₹8,733 Cr | 74.6 | 8.28% | ₹2,087 Cr | +80.7% |
| Remus Pharmaceuticals Limited | ₹941 Cr | 26.1 | 13.78% | — | +0.6% |
| Health X Platform Limited (Sastasundar Ventures Ltd) | ₹871 Cr | 752.7 | -0.18% | ₹484 Cr | -5.7% |
| Aptus Pharma Limited | ₹837 Cr | 156.8 | — | — | +754.0% |
| Vasa Denticity Limited | ₹797 Cr | 76.5 | 6.68% | ₹87 Cr | -21.4% |
| Bijoy Hans Ltd | ₹523 Cr | — | — | — | +128.4% |
| Speciality Medicines Limited | ₹149 Cr | 11.5 | — | — | — |
| Vijaypd Ceutical Limited | ₹136 Cr | 23 | 9.53% | — | — |
| Royal Sense Limited | ₹39 Cr | 5.6 | — | — | -71.2% |
Listed by market capitalisation. Ratios are shown for context only.
Aptus Pharma Limited is trading at ₹497.00, with a market capitalisation of ₹837 Cr.
Aptus Pharma Limited operates in the Health Care > Health Care Equipment and Services > Health Care Providers and Services space (Health Care Distributors > Pharmaceutical Product Distribution).
Aptus Pharma Limited has a P/E of 156.8.
Aptus Pharma Limited is listed on the BSE under the scrip code 544529.
Aptus Pharma Limited's share price is up 754.0% over one year and up 92.5% over three months. Its 52-week range is ₹58.20 to ₹510.90.
Promoters held 23.86% of Aptus Pharma Limited's shares as of Jun 2026, against 40.37% in Jun 2025 (−16.51 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.